Palomino Laboratories Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-1.4M | $-1.2M | $-742.6K | $-1.8M | $389.4K | $-985.2K |
| Depreciation & Amortization | $12.5K | $2.8K | — | — | — | — |
| Depreciation | $12.5K | $2.8K | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $100.5K | — | — | $1.3M | $155.0K | — |
| Net Cash from Operating Activities | $-1.1M | $-1.1M | $-894.2K | $-309.8K | $-84.1K | $3.1K |
| Investing Activities | ||||||
| Capital Expenditures | $941.3K | $318.3K | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-941.3K | $-318.3K | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $14.9M | $-30.0K | $1.1M | $6.5M | $1.7M | $20 |
| Net Change in Cash | $12.8M | $-1.5M | $224.9K | $6.2M | $1.6M | $3.1K |
| Free Cash Flow | $-2.1M | $-1.4M | — | — | — | — |